Klinikum Nürnberg, Cardiovascular Center, Paracelsus Medical University, Nuremberg, Germany.
Cardiology, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland; Cardiac Surgery, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland.
Int J Cardiol. 2022 Dec 1;368:56-61. doi: 10.1016/j.ijcard.2022.08.012. Epub 2022 Aug 6.
The present study is a sub-analysis of the multicenter, randomized PERSIST-AVR trial (PERceval Sutureless Implant versus Standard Aortic Valve Replacement) comparing the in-hospital and 1-year results of sutureless versus conventional stented bioprostheses in isolated surgical aortic valve replacement (SAVR) within two different surgical approaches: mini-sternotomy (MS) and full-sternotomy (FS).
A total of 819 patients (per-protocol population) underwent preoperative randomization to sutureless or stented biological valve at 47 centers worldwide. Sub-analysis on isolated SAVR was performed. Results were compared between sutureless and stented within the two different surgical approaches.
285 patients were implanted with Perceval (67% in MS) and 293 with stented valves (65% in MS). Sutureless group showed significantly reduced surgical times both in FS and MS. In-hospital results show no differences between Perceval and stented valves in FS, while a lower incidence of new-onset of atrial fibrillation (3.7% vs 10.8%) with Perceval in MS. After 1-year, use of sutureless valve showed a significant reduction of MACCE (5.2% vs 10.8%), stroke rate (1.0% vs 5.4%), new-onset of atrial fibrillation (4.2% vs 11.4%) and re-hospitalizations (21.8 days vs 47.6 days), compared to stented valves but presented higher rate of pacemaker implantation (11% vs 1.6%).
Sutureless bioprosthesis showed significantly reduced procedural times during isolated SAVR in both surgical approaches. Patients with sutureless valves and MS access showed also better 1-year outcome regarding MACCEs, stroke, re-hospitalization and new-onset atrial fibrillation, but presented a higher rate of permanent pacemaker implantation compared to patients with stented bioprosthesis.
本研究是多中心、随机的 PERSIST-AVR 试验(PERceval 无缝线植入物与标准主动脉瓣置换术比较)的亚分析,该试验比较了两种不同手术方法(微创胸骨切开术[MS]和全胸骨切开术[FS])中单瓣主动脉瓣置换术(SAVR)中无缝线与传统带支架生物瓣的住院和 1 年结果。
共有 819 例患者(按方案人群)在全球 47 个中心接受了术前随机分组,分为无缝线或带支架生物瓣。对孤立性 SAVR 进行了亚分析。结果在两种不同的手术方法中比较了无缝线与带支架的结果。
285 例患者植入了 Perceval(MS 中占 67%),293 例患者植入了带支架瓣膜(MS 中占 65%)。无缝线组在 FS 和 MS 中均显著缩短了手术时间。在 FS 中,Perceval 与带支架瓣膜之间的住院结果无差异,而在 MS 中,新发心房颤动的发生率较低(3.7% vs 10.8%)。在 1 年时,使用无缝线瓣膜可显著降低 MACCE(5.2% vs 10.8%)、卒中发生率(1.0% vs 5.4%)、新发心房颤动(4.2% vs 11.4%)和再住院率(21.8 天 vs 47.6 天),与带支架瓣膜相比,但带支架瓣膜的患者植入起搏器的比例较高(11% vs 1.6%)。
在两种手术方法中,无缝线生物瓣在孤立性 SAVR 中显著缩短了手术时间。采用无缝线瓣膜和 MS 入路的患者在 1 年时的 MACCEs、中风、再住院和新发心房颤动方面的结果也更好,但与带支架生物瓣的患者相比,植入永久性起搏器的比例更高。